PTO/SB/08A (08-03)

Approved for use through 7/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

12/20/2005 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for Form 1449/PTO				Complete if Known				
				Applica	ation Number	10/550,0	39	
INFORMATION DISCLOSURE				Filing Date		September 21, 2005  Michael Barry Gravestock  Not yet known		
STATEMENT BY APPLICANT (Use as many sheets as necessary)  SHEET of					amed inventor			
					it			
					ner Name	Not yet known		
					y Docket No.	100870-1P US		
	<del></del>	7	U.S. PATE	NT D	OCUMENTS			
Examiner Initials*	2 (if known)   Tubilosuori		Publication E MM-DD-YY			ne of Patentee or nt of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	ــــــــــــــــــــــــــــــــــــــ		FOREIGN PA	TENT	DOCUMENT	rs		
	1	Service Between		1		T	Pages, Columns, Lines,	T
Examiner Initials*	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (If known)		Publication Date MM-DD-YYYY		Name of Patentee or Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T⁰
wa	AA	WO 01/81350 A1		11-01-2001		AstraZeneca		
YC						AB AstraZeneca UK Ltd		
	AB	WO 02/081470 A1		10	-17-2002	AstraZeneca AB AstraZeneca UK Ltd		
	AC	EP 0352 781 A2/A3		01	-31-1990	E.I. Du Pont De Nemours and Company		
	AD	WO 99/64416 A2/A3		12-16-1999		Zeneca Ltd		
	AE WO 03/035648		05-01-2003		AstraZeneca AB AstraZeneca UK Ltd			
	AF	F WO 03/072576 A2/A3		09-	04-2003	AstraZeneca AB AstraZeneca UK Ltd		
▼	AG	WO 03/072575		09-	04-2003	AstraZeneca	<del> </del>	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kind Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CEP 1.97 and 1.98. The information is consistent to challe or cotain a baselia by the public which is to file for the patent.

YC

Examiner

/Yong Chu/

AB

**AstraZeneca UK Limited** 

Date

Considered

08/15/2006

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.